Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for 688488.SS and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 688488.SS and 80,000+ other tickers.
See exactly how 688488.SS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 688488.SS and 80,000+ other tickers.
Jiangsu Aidea Pharmaceutical Co., Ltd. specializes in the research, manufacturing, and commercialization of diverse pharmaceutical products. Its extensive offerings encompass a range of medications including folium sennae granules, powdered bacillus tablets, clindamycin hydrochloride capsules, sodium bicarbonate tablets, nitrendipine tablets, metronidazole tablets, compound gentamycin sulfate and procaine hydrochloride sulfate granules, and cefradine capsules. The company also provides pharmaceutical raw materials. Established in 2009, Jiangsu Aidea Pharmaceutical is headquartered in Yangzhou, China.
No recent news available.